Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.7.3477

Oxaliplatin Sensitizes OS Cells to TRAIL-induced Apoptosis Via Down-regulation of Mcl1  

Huang, Tao (Department of Orthopedics, The First Affiliated Hospital of China Medical University)
Gong, Wei-Hua (Beth Israel Deaconess Medical Center, Harvard Medical School)
Li, Xiu-Cheng (Department of Orthopedics, The First Affiliated Hospital of China Medical University)
Zou, Chun-Ping (Department of Orthopedics, The First Affiliated Hospital of China Medical University)
Jiang, Guang-Jian (Beth Israel Deaconess Medical Center, Harvard Medical School)
Li, Xu-Hui (Beth Israel Deaconess Medical Center, Harvard Medical School)
Qian, Hao (Department of Orthopedics, The First Affiliated Hospital of China Medical University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.7, 2012 , pp. 3477-3481 More about this Journal
Abstract
Purpose: To investigate the killing effect on OS cells of a combination of oxaliplatin and TRAIL and related molecular mechanisms. Methods: TRAIL and oxaliplatin were applied to OS732 cells singly or jointly and survival inhibition rates were measured by MTT assay, changes of cellular shape being assessed with inverted phase contrast and fluorescence microscopy. Apoptotic rates were analyzed by flow cytometry (FCM) and immunocytochemistry was used to examine Mcl1 expression of OS732 cells. Results: The survival inhibition rate of combined application of $100{\mu}g/ml$ TRAIL and $1{\mu}g/ml$ oxaliplatin on OS-732 cells was significantly higher than that of either agent singly (p<0.01). Changes of cellular shape and apoptotic rates also indicated apoptosis-inducing effects of combined application to be much stronger than those of individual application. Oxaliplatin had the effect of down-regulating Mcl1 expression and sensitizing OS cells to TRAIL-induced apoptosis. Conclusion: A combination of TRAIL and oxaliplatin exerts strong killing effects on OS-732 cells which might be related to down-regulation of Mcl1 expression.
Keywords
Osteosarcoma; TRAIL; oxaliplatin; apoptosis;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
연도 인용수 순위
1 Arlt MJ, Walters DK, Banke IJ, et al (2011). The antineoplastic antibiotic taurolidine promotes lung and liver metastasis in two syngeneic osteosarcoma mouse models and exhibits severe liver toxicity. Int J Cancer, 131, E804-12.
2 Beaty O, 3rd Berg S, Blaney S, et al (2010). A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer, 55, 440-5.   DOI
3 Bouralexis S, Findlay DM, Atkins GJ, et al (2003). Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer, 89, 206-14.   DOI
4 Bruland OS, and Pihl A (1997). On the current management of osteosarcoma. A critical evaluation and a proposal for a modified treatment strategy. Eur J Cancer 33, 1725-31.   DOI   ScienceOn
5 Brunat-Mentigny, M., and Kohler, R. (1993). [Osteosarcoma]. Rev Prat, 43, 2197-203.
6 Clairambault J, Claude D, Filipski E, Granda T, Levi F (2003). [Toxicity and anti-tumour efficacy of oxaliplatin on Glasgow osteosarcoma induced in mice: a mathematical model]. Pathol Biol (Paris), 51, 212-5.   DOI
7 Hartmann C, Weinel P, Schmid H, et al (2011). Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. J Pediatr Hematol Oncol, 33, 344-349.   DOI
8 El Fajoui Z, Toscano F, Jacquemin G et al (2011). Oxaliplatin sensitizes human colon cancer cells to TRAIL through JNK-dependent phosphorylation of Bcl-xL. Gastroenterology, 141, 663-73.   DOI
9 Geoerger B, Doz F, Gentet JC et al (2008). Phase I study of weekly oxaliplatin in relapsed or refractory pediatric solid malignancies. J Clin Oncol, 26, 4394-400.   DOI
10 Gores GJ, Kaufmann SH (2012). Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors. Genes Dev, 26, 305-11.   DOI
11 Jani TS, DeVecchio J, Mazumdar T, Agyeman A, Houghton JA (2010). Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem, 285, 19162-72.   DOI
12 Kim J H, Park B, Gupta SC, et al (2012). Zyflamend sensitizes tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and down-regulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding protein-homologous protein pathway. Antioxid Redox Signal, 16, 413-27.   DOI   ScienceOn
13 Moon MH, Jeong JK, Seo JS, et al (2011). Bisphosphonate enhances TRAIL sensitivity to human osteosarcoma cells via death receptor 5 upregulation. Exp Mol Med, 43, 138-145.   DOI
14 Kubista B, Erovic BM, Klinger H, Sulzbacher I, Trieb K (2004). CD9 expression is not a prognostic factor in human osteosarcoma. Cancer Lett, 209, 105-10.   DOI
15 Lin F, Wang Q, Yu W et al (2011). Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol, 7, 270-5.   DOI
16 Locklin RM, Federici E, Espina B, et al (2007). Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther, 6, 3219-28.   DOI
17 Pritchard DM, Berry D, Przemeck SM, et al (2008). Gastrin increases mcl-1 expression in type I gastric carcinoid tumors and a gastric epithelial cell line that expresses the CCK-2 receptor. Am J Physiol Gastrointest Liver Physiol, 295, G798-805.   DOI
18 Rassidakis GZ, Lai R, McDonnell TJ, et al (2002). Overexpression of Mcl-1 in anaplastic large cell lymphoma cell lines and tumors. Am J Pathol 160, 2309-10.   DOI
19 Seol DW (2011). p53-Independent up-regulation of a TRAIL receptor DR5 by proteasome inhibitors: a mechanism for proteasome inhibitor-enhanced TRAIL-induced apoptosis. Biochem Biophys Res Commun, 416, 222-5.   DOI
20 Rizza SA, Challagundla KB, Natesampillai S, et al (2011). TRAIL dependent fratricidal killing of gp120 primed hepatocytes by HCV core expressing hepatocytes. PLoS One, 6, e27171.   DOI
21 Song S, Choi K, Ryu, SW, Kang SW, Choi C (2011). TRAIL promotes caspase-dependent pro-inflammatory responses via PKCdelta activation by vascular smooth muscle cells. Cell Death Dis, 2, e223.   DOI
22 Takeda S, Iwai A, Nakashima M, et al (2007). LKB1 is crucial for TRAIL-mediated apoptosis induction in osteosarcoma. Anticancer Res, 27, 761-8.
23 Trieb K, Kotz R (2001). Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol, 33, 11-7.   DOI
24 Zhou W, Hu J, Tang H, et al (2011). Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors. BMC Cancer, 11, 485.   DOI
25 Van Valen F, Fulda S, Schafer KL, et al (2003). Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells vs. normal human cells. Int J Cancer, 107, 929-40.   DOI
26 Wiley SR, Schooley K, Smolak PJ, et al (1995). Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3, 673-82.   DOI   ScienceOn
27 Yuan JM, Li XD, Liu ZY, et al (2011). Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev, 12, 3465-9.
28 Zhang G, Li M, Jin J, Bai Y, Yang C (2011). Knockdown of S100A4 decreases tumorigenesis and metastasis in osteosarcoma cells by repression of matrix metalloproteinase-9. Asian Pac J Cancer Prev, 12, 2075-80.